Literature DB >> 18502333

Epigenetic dysregulation in thyroid neoplasia.

Tetsuo Kondo1, Sylvia L Asa, Shereen Ezzat.   

Abstract

Gain-of-function mutations in oncogenes have aided our understanding of the molecular mechanisms of thyroid carcinogenesis. Mutations or deletions cause inactivation of tumor suppressor genes in thyroid carcinomas. However, recent advances have disclosed the significance of epigenetic events in the development and progression of human tumorigenesis. Indeed, various tumor-suppressor genes and thyroid hormone-related genes are epigenetically silenced in thyroid tumors. This article reviews the evidence for epigenetic gene dysregulation in follicular cell-derived thyroid carcinomas including papillary thyroid carcinoma, follicular thyroid carcinoma, and undifferentiated thyroid carcinoma. The authors also discuss future applications of epigenetics as ancillary diagnostic tools and in the design of targeted therapies for thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502333     DOI: 10.1016/j.ecl.2007.12.002

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  10 in total

1.  Rap1 and its regulatory proteins: the tumor suppressor, oncogene, tumor suppressor gene axis in head and neck cancer.

Authors:  Rajat Banerjee; Nickole Russo; Min Liu; Elizabeth Van Tubergen; Nisha J D'Silva
Journal:  Small GTPases       Date:  2012-06-11

2.  Nucleophosmin delocalization in thyroid tumour cells.

Authors:  Annalisa Pianta; Cinzia Puppin; Nadia Passon; Alessandra Franzoni; Milena Romanello; Gianluca Tell; Carla Di Loreto; Stefania Bulotta; Diego Russo; Giuseppe Damante
Journal:  Endocr Pathol       Date:  2011-03       Impact factor: 3.943

3.  Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Ioanna Delladetsima; Ioanna Giannopoulou; Efstratios Patsouris; Stamatios Theocharis
Journal:  Tumour Biol       Date:  2013-07-20

4.  Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line.

Authors:  Federica Baldan; Catia Mio; Lorenzo Allegri; Cinzia Puppin; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Int J Endocrinol       Date:  2015-01-29       Impact factor: 3.257

5.  The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).

Authors:  Heng Niu; Jingyu Yang; Kunxian Yang; Yingze Huang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

6.  LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.

Authors:  Xiaomei Sui; Yana Sui; Yonghui Wang
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

7.  HOPX homeobox methylation in differentiated thyroid cancer and its clinical relevance.

Authors:  Erika Urbano Lima; Ileana G S Rubio; Joaquim Custodio Da Silva; Ana Luiza Galrão; Danielle Pêssoa; Taise Cerqueira Oliveira; Fabiane Carrijo; Igor Silva Campos; Luciano Fonseca Espinheira; Luiz Jose Sampaio; Claudio Rogerio Lima; Janete Maria Cerutti; Helton Estrela Ramos
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

8.  Retracted Article: Down-regulation of Rab10 inhibits hypoxia-induced invasion and EMT in thyroid cancer cells by targeting HIF-1α through the PI3K/Akt pathway.

Authors:  Zhenyu Zhou; Yang Liu; Zhuang Hu; Mingde Ma; Liang Chang
Journal:  RSC Adv       Date:  2018-09-12       Impact factor: 4.036

9.  HORMAD2 methylation-mediated epigenetic regulation of gene expression in thyroid cancer.

Authors:  Qiuyu Lin; Sen Hou; Feng Guan; Chenghe Lin
Journal:  J Cell Mol Med       Date:  2018-07-24       Impact factor: 5.310

Review 10.  Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application.

Authors:  Sule Canberk; Ana Rita Lima; Mafalda Pinto; Paula Soares; Valdemar Máximo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.